Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129.

Publication Type:

Journal Article


Pediatric blood & cancer, Volume 53, Issue 6, p.1005-10 (2009)


2009, Adolescent, Center-Authored Paper, Child, Child, Preschool, Clinical Research Division, Cytarabine, Daunorubicin, Female, Humans, Infant, Leukemia, Promyelocytic, Acute, Male, Remission Induction, Survival Analysis, Treatment Outcome, Tretinoin


This report focuses on the children enrolled on the first North American Intergroup study of APL (INT0129). This study was designed to compare the rates of CR, disease-free survival (DFS), overall survival (OS) and toxicity of therapy with all-trans-retinoic acid (ATRA) for remission induction and/or maintenance compared to conventional chemotherapy in patients with previously untreated APL.